ATE320493T1 - Modifizierung des hepatitis b kernantigens - Google Patents

Modifizierung des hepatitis b kernantigens

Info

Publication number
ATE320493T1
ATE320493T1 AT01943625T AT01943625T ATE320493T1 AT E320493 T1 ATE320493 T1 AT E320493T1 AT 01943625 T AT01943625 T AT 01943625T AT 01943625 T AT01943625 T AT 01943625T AT E320493 T1 ATE320493 T1 AT E320493T1
Authority
AT
Austria
Prior art keywords
hepatitis
hbcag
protein
core antigen
modification
Prior art date
Application number
AT01943625T
Other languages
English (en)
Inventor
Mark Page
Jing-Li Li
Paul Pumpens
Galina Borisova
Original Assignee
Ucb Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015308A external-priority patent/GB0015308D0/en
Priority claimed from GB0024544A external-priority patent/GB0024544D0/en
Application filed by Ucb Pharma Ltd filed Critical Ucb Pharma Ltd
Application granted granted Critical
Publication of ATE320493T1 publication Critical patent/ATE320493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01943625T 2000-06-22 2001-06-22 Modifizierung des hepatitis b kernantigens ATE320493T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015308A GB0015308D0 (en) 2000-06-22 2000-06-22 Modification of hepatitis B core antigen
GB0024544A GB0024544D0 (en) 2000-10-06 2000-10-06 Modification of hepatitus B core antigen

Publications (1)

Publication Number Publication Date
ATE320493T1 true ATE320493T1 (de) 2006-04-15

Family

ID=26244528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943625T ATE320493T1 (de) 2000-06-22 2001-06-22 Modifizierung des hepatitis b kernantigens

Country Status (11)

Country Link
US (1) US20040054139A1 (de)
EP (1) EP1294893B1 (de)
JP (1) JP2004500868A (de)
AT (1) ATE320493T1 (de)
AU (2) AU2001266163B2 (de)
CA (1) CA2413546C (de)
DE (1) DE60117978T2 (de)
DK (1) DK1294893T3 (de)
ES (1) ES2260235T3 (de)
PT (1) PT1294893E (de)
WO (1) WO2001098333A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511075A (ja) * 1999-10-08 2003-03-25 セルテック ファーマ ユアロップ リミテッド 免疫原の設計
ATE336502T1 (de) * 2000-04-07 2006-09-15 Univ Leeds Hepatitis b kernprotein fusionsproteine
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
WO2003072731A2 (en) * 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
IN2008CN05409A (de) 2002-07-18 2015-10-02 Cytos Biotechnology Ag
WO2004016282A1 (en) 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004084940A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
EP1651258B1 (de) * 2003-07-30 2014-03-19 Vaccine Research Institute of San Diego Hepatitis virus kapsid-proteine als vakzine-plattformen und anwendungsverfahren dafür
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
EP1694301A4 (de) * 2003-12-02 2009-11-18 Cytimmune Sciences Inc Verfahren und zusammensetzungen zur herstellung von monoklonalen antikörpern
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
IN2012DN00446A (de) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
NZ710626A (en) 2009-09-03 2017-03-31 Pfizer Vaccines Llc Pcsk9 vaccine
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
KR102190180B1 (ko) 2011-04-15 2020-12-11 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｄｎａ 백신
KR102205077B1 (ko) * 2012-08-31 2021-01-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｖｅｇｆ-특이적 에피토프 및/또는 안지오포이에틴-2-특이적 에피토프를 함유하는 ｄｎａ 백신
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
WO2015133467A1 (ja) * 2014-03-06 2015-09-11 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
SG11202008508QA (en) 2018-03-06 2020-10-29 Precigen Inc Hepatitis b vaccines and uses of the same
US11261216B2 (en) * 2018-12-28 2022-03-01 The Board Of Trustees Of The Leland Stanford Junior University Engineered hepatitis B core polypeptide
WO2021045969A1 (en) * 2019-08-29 2021-03-11 Vir Biotechnology, Inc. Hepatitis b virus vaccines
IL290999B1 (en) 2019-09-30 2024-10-01 Gilead Sciences Inc HBV vaccines and HBV treatment methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
DE69929470T2 (de) * 1998-11-05 2006-08-24 Powderject Vaccines, Inc., Madison Genkonstrukte für genimmunisierung

Also Published As

Publication number Publication date
JP2004500868A (ja) 2004-01-15
DE60117978T2 (de) 2006-11-02
CA2413546C (en) 2011-06-14
ES2260235T3 (es) 2006-11-01
AU6616301A (en) 2002-01-02
DK1294893T3 (da) 2006-07-03
DE60117978D1 (de) 2006-05-11
US20040054139A1 (en) 2004-03-18
WO2001098333A3 (en) 2002-03-28
PT1294893E (pt) 2006-08-31
EP1294893B1 (de) 2006-03-15
AU2001266163B2 (en) 2006-07-13
WO2001098333A2 (en) 2001-12-27
EP1294893A2 (de) 2003-03-26
CA2413546A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
ATE320493T1 (de) Modifizierung des hepatitis b kernantigens
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
ATE323758T1 (de) Attenuierte lebendimpfstoffe
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
DK1283887T3 (da) Kimære Arterivirus-lignende partikler
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
DK1035133T3 (da) Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
HK1052368A1 (zh) 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
WO2001092311A3 (fr) Bibliotheques peptidiques combinatoires convergentes et leur applicaton a la vaccination contre le virus de l'hepatite c
SE0002498D0 (sv) Papillomavirus vaccine
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus
DE60036563D1 (de) Nukleoprotein des toscanavirus
AU4394101A (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1294893

Country of ref document: EP

REN Ceased due to non-payment of the annual fee